Page 536 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

90. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. with low-molecular-weight heparin and related drugs. Semin
Identification and preliminary validation of predictors of major Thromb Hemost. February 2004;30(suppl 1):69-80.
bleeding in hospitalized patients starting anticoagulant therapy. 105. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of
Am J Med. April 1987;82(4):703-713. recombinant hirudin with a low-molecular-weight heparin to
91. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency prevent thromboembolic complications after total hip replace-
and clinical significance of thrombocytopenia complicating ment. N Engl J Med. November 6, 1997;337(19):1329-1335.
critical illness: a systematic review. Chest. February 2011;139(2): 106. Crowther MA, Warkentin TE. Bleeding risk and the manage-
271-278. ment of bleeding complications in patients undergoing antico-
92. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: agulant therapy: focus on new anticoagulant agents. Blood. May
a critical review and pooled analysis. Am J Med Sci. April 1993; 15, 2008;111(10):4871-4879.
305(4):208-215. 107. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for
93. Warkentin TE. Heparin-induced thrombocytopenia in critically thrombosis and major bleeding in an observational study in 181
ill patients. Crit Care Clin. 2011;27(4):805-823. patients with heparin-induced thrombocytopenia treated with
94. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from lepirudin. Blood. September 1, 2006;108(5):1492-1496.
patients with heparin-induced thrombocytopenia generate plate- 108. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M.
let-derived microparticles with procoagulant activity: an expla- Heparin-induced thrombocytopenia with thromboembolic
nation for the thrombotic complications of heparin-induced complications: meta-analysis of 2 prospective trials to assess the
thrombocytopenia. Blood. December 1, 1994;84(11):3691-3699. value of parenteral treatment with lepirudin and its therapeutic
95. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme aPTT range. Blood. August 1, 2000;96(3):846-851.
GA, Horsewood P. Immunoglobulin G from patients with hep- 109. Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the
arin-induced thrombocytopenia binds to a complex of heparin approved dosing schedule too high? J Thromb Haemost.
and platelet factor 4. Blood. June 1, 1994;83(11):3232-3239. November 2005;3(11):2593-2596.
96. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced
thrombocytopenia in patients treated with low-molecular- 110. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, random-
weight heparin or unfractionated heparin. N Engl J Med. May ized study of argatroban versus heparin as adjunct to tissue
18, 1995;332(20):1330-1335. plasminogen activator (TPA) in acute myocardial infarction:
myocardial infarction with novastan and TPA (MINT) study.
97. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler J Am Coll Cardiol. June 1999;33(7):1879-1885.
P, Greinacher A. Gender imbalance and risk factor interactions
in heparin-induced thrombocytopenia. Blood. November 1, 111. Harenberg J, Marx S, Krejczy M, Wehling M. New antico-
2006;108(9):2937-2941. agulants—promising and failed developments. Br J Pharmacol.
98. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher 2012;165(2):363-372.
A. Evaluation of pretest clinical score (4 T’s) for the diagnosis 112. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous
of heparin-induced thrombocytopenia in two clinical settings. fondaparinux versus intravenous unfractionated heparin in
J Thromb Haemost. April 2006;4(4):759-765. the initial treatment of pulmonary embolism. N Engl J Med.
99. Simonneau G, Sors H, Charbonnier B, et al. A comparison of October 30, 2003;349(18):1695-1702.
low-molecular-weight heparin with unfractionated heparin 113. Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban
for acute pulmonary embolism. The THESEE Study Group. for the treatment of symptomatic pulmonary embolism. N Engl
Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie J Med. 2012;366(14):1287-1297.
Pulmonaire. N Engl J Med. September 4, 1997;337(10):663-669. 114. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller
100. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular- HR, Levi M. Reversal of rivaroxaban and dabigatran by pro-
weight heparin compared with intravenous unfractionated thrombin complex concentrate/clinical perspective. Circulation.
heparin for treatment of pulmonary embolism: a meta- analysis October 4, 2011;124(14):1573-1579.
of randomized, controlled trials. Ann Intern Med. February 3, 115. Prandoni P. Anticoagulant treatment of pulmonary embolism:
2004;140(3):175-183. impact and implications of the EINSTEIN PE study. Eur J
101. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Haematol. 2012;89(4):281-287.
Comparison of efficacy and safety of low molecular weight 116. Moser KM. Venous thromboembolism. Am Rev Respir Dis.
heparins and unfractionated heparin in initial treatment January 1990;141(1):235-249.
of deep venous thrombosis: a meta-analysis. BMJ. July 30,
1994;309(6950):299-304. 117. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of
102. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight hep- vena caval filters in the prevention of pulmonary embolism
in patients with proximal deep-vein thrombosis. Prevention
arin versus a coumarin for the prevention of recurrent venous du Risque d'Embolie Pulmonaire par Interruption Cave Study
thromboembolism in patients with cancer. N Engl J Med. July Group. N Engl J Med. February 12, 1998;338(7):409-415.
10, 2003;349(2):146-153.
103. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low- 118. Streiff MB. Vena caval filters: a comprehensive review. Blood.
June 15, 2000;95(12):3669-3677.
molecular-weight heparin and warfarin for the secondary pre-
vention of venous thromboembolism in patients with cancer: a 119. Asch MR. Initial experience in humans with a new retrievable
randomized controlled study. Arch Intern Med. August 12-26, inferior vena cava filter. Radiology. December 2002;225(3):835-844.
2002;162(15):1729-1735. 120. Millward SF, Bhargava A, Aquino J Jr, et al. Gunther Tulip filter:
104. Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. preliminary clinical experience with retrieval. J Vasc Interv
Decreased prevalence of heparin-induced thrombocytopenia Radiol. January 2000;11(1):75-82.

Section03-O-ref.indd 4 1/20/2015 7:10:28 AM